Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

201 to 215 of 215 results

EU Commission unveils 12 concrete actions against antimicrobial resistance for the next five years

17-11-2011

With about 25,000 patients dying per year in the European Union from infections caused by drug resistant…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulationResearch

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases

16-11-2011

Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies

15-11-2011

In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen

31-10-2011

US advocacy group Public Citizen has sent a petition to the Food and Drug Administration calling on the…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

EFPIA supports a new R&D model to tackle antimicrobial resistance

27-10-2011

A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy

26-10-2011

US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news

20-10-2011

UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI

18-10-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections

03-10-2011

There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company…

Antibiotics and Infectious diseasesEraxisPfizerPharmaceuticalResearchVfend

More news from EMA/CHMP September meeting

26-09-2011

Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA

15-09-2011

The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report

14-09-2011

Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

EU launches development and cooperation projects with South Africa, including AIDS and TB

12-09-2011

European Development Commissioner Andris Piebalgs is visiting South Africa from September 13 to 16 to…

Anti-viralsAntibiotics and Infectious diseasesEuropeFinancialHealthcarePharmaceuticalRest of the World

GlaxoSmithKline partners with BARDA to develop new class of antibiotic; amends deal with Anacor

08-09-2011

The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority…

Anacor PharmaceuticalAntibiotics and Infectious diseasesFinancialGlaxoSmithKlineLicensingPharmaceuticalResearchTropical diseases

201 to 215 of 215 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top